Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Ravi Vij, MBBS, MD, Michael Savona, MD, David S. Siegel, MD PhD, Jonathan L. Kaufman, MD, Ashraf Badros, MD, Irene M. Ghobrial, MD, Agne Paner, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD PhD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Linda L. Neuman, MD MBA, Ju RueyJiuan Lee, PhD, Jesus G. Berdeja, MD

Blood (2014) 124 (21): 34.

https://doi.org/10.1182/blood.V124.21.34.34

Published: 2014

Journal Articles

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

Jesus Berdeja, MD, Sundar Jagannath, MD, Jeffrey Zonder, MD, Ashraf Badros, MD, Jonathan L. Kaufman, MD, Robert Manges, MD, Mark Lynch, PhD, Eric Bleickardt, MD, Prashni Paliwal, PhD, Ravi Vij, MD

Blood (2014) 124 (21): 2119.

https://doi.org/10.1182/blood.V124.21.2119.2119

Published: 2014

Journal Articles

Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)

Ashraf Badros, MD, Sunita Philip, Patricia Lesho, Mariola Sadowska, Dianna Weikel, Timothy Meiller, Rena Lapidus, Lisa Hester, Todd Milliron, Olga Goloubeva

Blood (2013) 122 (21): 3153.

https://doi.org/10.1182/blood.V122.21.3153.3153

Published: 2013

Journal Articles

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Irene M. Ghobrial, MD, Jonathan L. Kaufman, MD, David S. Siegel, MD, PhD, Ravi Vij, MD, Ashraf Badros, MD, Linda Neuman, MD, Hansen Wong, PhD, Janet Anderl, MS, Michael Savona, MD

Blood (2013) 122 (21): 3184.

https://doi.org/10.1182/blood.V122.21.3184.3184

Published: 2013

Journal Articles

Characteristics and Outcome Of Multiple Myeloma (MM) In African Americans (AA) Receiving Novel Agents and Autologous Stem Cell Transplantation (ASCT)

Vishal Bhatnagar, MD, Yin Wu, MD, Olga Goloubeva, Kathleen Ruehle, RN, Todd Milliron, Saul Yanovich, MD, Aaron P. Rapoport, MD, Ashraf Badros, MD

Blood (2013) 122 (21): 2951.

https://doi.org/10.1182/blood.V122.21.2951.2951

Published: 2013

Journal Articles

Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses

Blood (2013) 122 (21): 766.

https://doi.org/10.1182/blood.V122.21.766.766

Published: 2013

Journal Articles

Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib

Blood (2013) 122 (21): 3189.

https://doi.org/10.1182/blood.v122.21.3189.3189

Published: 2013

Journal Articles

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

Irene M. Ghobrial, M.D., Jeffrey Matous, MD, Swaminathan Padmanabhan, MD, Ashraf Badros, MD, Robert Schlossman, MD, Stacey Chuma, RN, Renee Leduc1, Marybeth Nelson, PA, Kelly O’Connor, Amy Sam, Brianna Harris, Jacob Soumerai, Diane Warren, Ann Birner, Nikhil Munshi, MD, Steven P. Treon, MD, PhD, Kenneth C. Anderson, MD, Paul Richardson, MD

Blood (2008) 112 (11): 832.

https://doi.org/10.1182/blood.V112.11.832.832

Published: 2008

Journal Articles

High Incidence of BK-Virus-Related Hemorrhagic Cystitis after Busulfan/Fludarabine Myeloablative Conditioning in Allogeneic Stem Cell Transplantation Recipients.

Gorgun Akpek, MD, MHS, Ashraf Badros, MD, Aaron P. Rapoport, MD, Kathleen Ruehle, RN, Kristen Barton, RN, Barry Meisenberg, MD, Saul Yanovich, MD

Blood (2006) 108 (11): 5254.

https://doi.org/10.1182/blood.V108.11.5254.5254

Published: 2006

Journal Articles

Neurotoxicity of Bortezomib Therapy in Multiple Myeloma (MM): A Single Center Experience.

Ashraf Badros, MD, Jay S. Dalal, MD, Olga Goloubeva, PhD, Jenni Thompson, Phrm.D., Kelly Yager, RN, Can Ilyas, MD, Aaron P. Rapoport, MD, Robert G. Fenton, MD, PhD, Gorgun Akpek, MD, Saul Yanovich, MD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 3534.

https://doi.org/10.1182/blood.V108.11.3534.3534

Published: 2006

Journal Articles

Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).

Ashraf Badros, MD, Olga Goloubeva, PhD, Dianna Weikel, DDS, Aaron P. Rapoport, MD, Gorgun Akpek, MD, Saul Yanovich, MD, Timothy Meiller, DDS, PhD, Edward Sausville, MD, PhD

Blood (2006) 108 (11): 5026.

https://doi.org/10.1182/blood.V108.11.5026.5026

Published: 2006

Journal Articles

A Phase I Trial of Oblimersen Sodium (G3139) for Relapsed or Refractory Waldenstrom Macroglobulinemia.

Morie Abraham Gertz, MD, Susan M. Geyer, PhD, Brad S. Kahl, MD, Ashraf Badros, MD, Craig Reeder, MD, Charles Erlichman, MD

Blood (2004) 104 (11): 2407.

https://doi.org/10.1182/blood.V104.11.2407.2407

Published: 2004

Journal Articles

Results of a Phase I/II Randomized Immunotherapy Trial Testing Adoptive Transfer of Co-Stimulated Autologous T Cells and Pneumococcal Conjugate Vaccine (PCV) Immunization after Autotransplantation for Myeloma (MM).

Alan Cross, MD, Aaron P. Rapoport, MD, Bruce L. Levine, Ph.D., Edward A. Stadtmauer, M.D., Carl H. June, MD, PhD, Dean Mann, MD, Carl Frasch, MD, Christian Lynch, BA, Ashraf Badros, MD, Lisa Chrisley, RN, Julio Cotte, BA, Rebecca Mair, BA, Joanne Hinkle, RN, Lei Zhang, MD, Robert Edelman, MD

Blood (2004) 104 (11): 5088.

https://doi.org/10.1182/blood.V104.11.5088.5088

Published: 2004

Journal Articles

Adoptive Transfer of Ex Vivo Costimulated Autologous T-Cells in Conjunction with Pneumococcal Conjugate Vaccine Immunizations Accelerates Post-Transplant T-Cell Recovery after Autotransplantation for Myeloma: Results of a Randomized Study.

Blood (2004) 104 (11): 439.

https://doi.org/10.1182/blood.V104.11.439.439

Published: 2004

NARROW

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study

Cytokine Alteration In Multiple Myeloma (MM) Patients and Bisphosphonate (BP)-Related Osteonecrosis Of The Jaw (BRONJ)

Clinical Profile Of Single-Agent Modified-Release Oprozomib Tablets In Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Characteristics and Outcome Of Multiple Myeloma (MM) In African Americans (AA) Receiving Novel Agents and Autologous Stem Cell Transplantation (ASCT)

Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses

Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib

Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia

High Incidence of BK-Virus-Related Hemorrhagic Cystitis after Busulfan/Fludarabine Myeloablative Conditioning in Allogeneic Stem Cell Transplantation Recipients.

Neurotoxicity of Bortezomib Therapy in Multiple Myeloma (MM): A Single Center Experience.

Interruption of Bisphosphonates (BP) Therapy in Multiple Myeloma (MM) Patients and Osteonecrosis of the Jaw (ONJ).

A Phase I Trial of Oblimersen Sodium (G3139) for Relapsed or Refractory Waldenstrom Macroglobulinemia.

Results of a Phase I/II Randomized Immunotherapy Trial Testing Adoptive Transfer of Co-Stimulated Autologous T Cells and Pneumococcal Conjugate Vaccine (PCV) Immunization after Autotransplantation for Myeloma (MM).

Adoptive Transfer of Ex Vivo Costimulated Autologous T-Cells in Conjunction with Pneumococcal Conjugate Vaccine Immunizations Accelerates Post-Transplant T-Cell Recovery after Autotransplantation for Myeloma: Results of a Randomized Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only